丙戊酸减小创伤性脑损伤、失血性休克与多发伤猪模型的脑病灶并改善神经功能恢复
该临床前研究将5头约克夏猪纳入脑损伤、失血性休克与多发伤模型,休克2小时后分别以等渗氯化钠溶液(容量为失血量的3倍)或等渗氯化钠溶液+丙戊酸(150 mg/kg)复苏。丙戊酸组在伤后第1至5天神经功能损害显著更轻,伤后第3天脑病灶更小(等渗氯化钠溶液组4956±1511 mm vs 丙戊酸组828±279 mm,p=0.047),伤后第10天两组病灶无显著差异,30天内所有动物神经功能恢复至基线。丙戊酸组神经认知恢复更快,最大血药浓度145±38.2 mg/L、曲线下面积616±150 hour·mg/L、半衰期1.70±0.12小时。作者认为丙戊酸安全、可减小脑病灶并减轻神经损伤,且获益在可临床转化的血清浓度下实现。
要点
- 在脑损伤、失血性休克与多发伤猪模型中,丙戊酸150 mg/kg单次给药使伤后第3天脑病灶从等渗氯化钠溶液组的4956±1511 mm减小至828±279 mm(p=0.047)。
- 丙戊酸组伤后第1至5天神经功能损害显著更轻,伤后第10天两组病灶大小无显著差异,30天内所有动物恢复至基线神经功能。
- 丙戊酸组神经认知恢复更快:开始测试时间3.6±1.5天 vs 6.2±1.6天(p=0.002),任务掌握时间4.8±0.5天 vs 7.0±1.0天(p=0.03)。
- 丙戊酸最大血药浓度145±38.2 mg/L、曲线下面积616±150 hour·mg/L、半衰期1.70±0.12小时;作者认为该浓度具临床可转化性。
- 作者结论为丙戊酸在該猪模型中安全、可减小脑病灶并减轻神经损伤;证据等级为治疗性(临床前研究)。
适用人群与场景
- 约克夏猪(每队列n=5),遭受创伤性脑损伤、失血性休克与多发伤(肝脾损伤、肋骨骨折、腹直肌挤压伤)。
处置流程与药物剂量
- 动物维持低血容量性休克2小时后,以等渗氯化钠溶液(容量=失血量的3倍)或等渗氯化钠溶液+丙戊酸(150 mg/kg)复苏;丙戊酸为单次给药。
研究设计与关键结果
- 临床前研究:约克夏猪每队列n=5,遭受创伤性脑损伤、失血性休克与多发伤,比较等渗氯化钠溶液复苏与等渗氯化钠溶液+丙戊酸(150 mg/kg);两组休克严重程度与复苏反应相似。
- 主要神经功能结果:丙戊酸组伤后第1至5天神经功能损害显著更轻。
- 脑病灶大小:伤后第3天等渗氯化钠溶液组4956±1511 mm vs 丙戊酸组828±279 mm(p=0.047);伤后第10天两组无显著差异。
- 神经认知恢复:开始测试时间等渗氯化钠溶液组6.2±1.6天 vs 丙戊酸组3.6±1.5天(p=0.002);任务掌握时间等渗氯化钠溶液组7.0±1.0天 vs 丙戊酸组4.8±0.5天(p=0.03)。
- 30天观察期内所有动物恢复至基线神经功能;丙戊酸最大血药浓度145±38.2 mg/L、曲线下面积616±150 hour·mg/L、半衰期1.70±0.12小时。
证据类型、等级与局限
- 证据类型:临床前研究(猪模型),证据等级为治疗性(临床前研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为,在遭受创伤性脑损伤、失血性休克与多发伤的猪模型中,丙戊酸治疗安全、可减小脑病灶并减轻神经损伤,且获益在可临床转化的血清浓度下实现;该结论来自临床前研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We have previously shown that treatment with valproic acid (VPA) decreases brain lesion size in swine models of traumatic brain injury (TBI) and controlled hemorrhage. To translate this treatment into clinical practice, validation of drug efficacy and evaluation of pharmacologic properties in clinically realistic models of injury are necessary. In this study, we evaluate neurologic outcomes and perform pharmacokinetic analysis of a single dose of VPA in swine subjected to TBI, hemorrhagic shock, and visceral hemorrhage.
METHODS: Yorkshire swine (n = 5/cohort) were subjected to TBI, hemorrhagic shock, and polytrauma (liver and spleen injury, rib fracture, and rectus abdominis crush). Animals remained in hypovolemic shock for 2 hours before resuscitation with isotonic sodium chloride solution (ISCS; volume = 3× hemorrhage) or ISCS + VPA (150 mg/kg). Neurologic severity scores were assessed daily for 30 days, and brain lesion size was measured via magnetic resonance imaging on postinjury days (PID) 3 and 10. Serum samples were collected for pharmacokinetic analysis.
RESULTS: Shock severity and response to resuscitation were similar in both groups. Valproic acid-treated animals demonstrated significantly less neurologic impairment between PID 1 to 5 and smaller brain lesions on PID 3 (mean lesion size ± SEM, mm: ISCS = 4,956 ± 1,511 versus ISCS + VPA = 828 ± 279; p = 0.047). No significant difference in lesion size was identified between groups at PID 10 and all animals recovered to baseline neurologic function during the 30-day observation period. Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03). The mean ± SD maximum VPA concentrations, area under the curve, and half-life were 145 ± 38.2 mg/L, 616 ± 150 hour·mg/L, and 1.70 ± 0.12 hours.
CONCLUSIONS: In swine subjected to TBI, hemorrhagic shock, and polytrauma, VPA treatment is safe, decreases brain lesion size, and reduces neurologic injury compared to resuscitation with ISCS alone. These benefits are achieved at clinically translatable serum concentrations of VPA.
LEVEL OF EVIDENCE: Therapeutic (preclinical study).
参考来源
- Nikolian VC, Georgoff PE, Pai MP, et al. Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. J Trauma Acute Care Surg. 2017. PMID: 28697014. doi:10.1097/TA.0000000000001612
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。